CurrentBlue Cross Blue Shield of VermontPolicy 8.01.VT10

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Customize your policy alerts

Sign up for bcbsvermont Policy 8.01.VT10 alerts

Get alerted when Policy 8.01.VT10 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity, prior approval, documentation, and coding requirements for proton or helium-ion radiotherapy used to treat benign or malignant tumors and hematologic malignancies. Coverage varies by tumor type, patient age, clinical circumstances, and whether the application is considered investigational.

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyCharged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Policy CodePolicy 8.01.VT10

Change TypeUpdated indications and criteria

Effective DateFebruary 1, 2026

Last ReviewOct 1, 2025

Next Review DateOctober 1, 2026

Key ActionObtain prior approval and submit the required clinical documentation for listed stereotactic radiosurgery and proton treatment-delivery services.

SourceLink

POLICY UPDATE CHANGES

New indications and criteria were added for charged-particle radiotherapy, including circumstances involving normal-tissue sparing and avoidance of cumulative radiation exposure.

21 and youngerChildren eligible for curative or palliative treatment

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield of VermontPolicy 8.01.VT10

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Customize your policy alerts

Sign up for bcbsvermont Policy 8.01.VT10 alerts

Get alerted when Policy 8.01.VT10 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyCharged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Policy CodePolicy 8.01.VT10

Change TypeUpdated indications and criteria

Effective DateFebruary 1, 2026

Last ReviewOct 1, 2025

Next Review DateOctober 1, 2026

Key ActionObtain prior approval and submit the required clinical documentation for listed stereotactic radiosurgery and proton treatment-delivery services.

SourceLink

POLICY UPDATE CHANGES

New indications and criteria were added for charged-particle radiotherapy, including circumstances involving normal-tissue sparing and avoidance of cumulative radiation exposure.

21 and youngerChildren eligible for curative or palliative treatment

22-39 yearsAdolescents and young adults included

24 mm × 14 mmMaximum eligible ocular tumor size

Over age 21Other adult applications are investigational

8Treatment codes requiring prior approval

Medical Necessity and Coverage Criteria

General medically necessary indications

Charged-particle irradiation may be considered medically necessary when at least one of the following general indications applies:

At least one general indication

Age-based treatment: Curative or palliative treatment of benign or malignant tumors or hematologic malignancies in children 21 years and younger or adolescents and young adults aged 22 through 39 yearsAge <=21 or 22-39 years
High-risk genetic syndrome: The patient has a genetic syndrome such as NF-1, a deleterious ATM mutation, Li-Fraumeni syndrome, or retinoblastoma, and minimizing the total volume of radiation is critical
Genetic mutation risk: The patient has another genetic mutation, such as BRCA1/2 or Lynch syndrome, associated with an increased risk of developing second cancers
Re-irradiation: A previously treated field is being re-irradiated and the dose tolerance of surrounding structures would be exceeded by standard radiation therapy
Medically inoperable patient: The patient is medically inoperable but requires dose escalation typically achieved with surgery
Primary bone tumor: The patient has a primary malignant or benign bone tumor

Central nervous system indications

Charged-particle irradiation may be considered medically necessary when at least one of the following central nervous system indications applies:

At least one central nervous system indication

Unresectable CNS cancer: The patient has a benign or malignant central nervous system cancer that cannot be completely resected
Ocular tumor: The patient has an ocular tumor, including intraocular or uveal melanoma, up to 24 mm in diameter and 14 mm in height, with no evidence of metastasis or extrascleral extensionDiameter <=24 mm; height <=14 mm; no metastasis or extrascleral extension
Skull-base tumor: The tumor approaches or involves the base of the skull, such as a chordoma or chondrosarcoma

Head and neck, thoracic, and liver indications

Charged-particle irradiation may be considered medically necessary when at least one of the following site-specific indications applies:

At least one site-specific indication

Advanced or unresectable head and neck cancer: The patient has an advanced-stage and/or unresectable malignant head and neck lesion
Nasopharyngeal, nasal, or sinus cancer: The patient has cancer of the nasopharynx, nasal cavity, or paranasal/accessory sinuses
Esophageal cancer: The patient has a primary cancer of the esophagus
Mediastinal tumor: The patient has a primary tumor of the mediastinum, including a thymic tumor, mediastinal lymphoma, or sarcoma

Normal-tissue-sparing and dose-distribution criteria

Charged-particle treatment is considered reasonable when photon-based radiotherapy cannot adequately spare surrounding normal tissue and charged-particle therapy provides added clinical benefit. At least one of the following circumstances must apply:

At least one dose-distribution or prior-radiation circumstance

Critical-structure proximity: The target is close to one or more critical structures and a steep dose gradient outside the target is needed to avoid exceeding the tolerance dose of the critical structure or structures
Dose inhomogeneity reduction: A reduction in dose inhomogeneity across a large treatment volume is needed to avoid an excessive dose hotspot and lessen the risk of excessive early or late normal-tissue toxicity
Integral-dose toxicity avoidance: A photon-based technique would increase the probability of clinically meaningful normal-tissue toxicity by exceeding an integral dose-based metric associated with toxicity

Investigational applications

All other applications of charged-particle irradiation in adults are investigational.

Investigational adult application: The patient is over age 21 and the requested charged-particle application is not one of the medically necessary indications listed in the policyAge >21

Examples include clinically localized prostate cancer and non-small-cell lung cancer at any stage or for recurrence.

The ocular tumor indication applies to intraocular or uveal melanoma and other ocular tumors measuring up to 24 mm in diameter and 14 mm in height, provided there is no metastasis or extrascleral extension. Tumors exceeding either size limit, or tumors with metastasis or extrascleral extension, are outside this stated indication.

Clinically localized prostate cancer and non-small-cell lung cancer—including non-small-cell lung cancer at any stage or when treated for recurrence—are considered investigational applications under this policy.

For adults over age 21, all other charged-particle irradiation applications that are not among the policy’s listed medically necessary indications are considered investigational.

Coding and Eligibility Parameters

Covered CPT CodesCPTCovered

61796	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 simple cranial lesion
61797	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, simple (List separately in addition to code for primary procedure)
61798	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 complex cranial lesion
61799	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional cranial lesion, complex (List separately in addition to code for primary procedure)
63620	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion
63621	Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); each additional spinal lesion (List separately in addition to code for primary procedure)
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

Eligible ocular tumor size

Maximum diameterUp to 24 mm

Maximum heightUp to 14 mm

Additional ocular criteriaNo evidence of metastasis or extrascleral extension

Covered pediatric and young adult age range

Children21 years and younger

Adolescents and young adults (AYA)Aged 22 through 39 years

Covered age rangeChildren 21 years and younger and AYA aged 22-39 years

Authorization, Documentation, and Audit Requirements

Prior Authorization

Prior Approval Required

Prior approval is required for the listed stereotactic radiosurgery and proton treatment-delivery services. Benefits remain subject to the member’s contract and applicable limitations.

CPT 61796, 61797, 61798, and 61799 — stereotactic radiosurgery for cranial lesions.
CPT 63620 and 63621 — stereotactic radiosurgery for spinal lesions.
CPT 77520, 77522, 77523, and 77525 — proton treatment delivery.

Documentation Required

Required Medical-Record Documentation

The medical record must support the applicable clinical indication and include the member’s relevant cancer-treatment history and treatment prescription. Submit complete records with the authorization request.

Documentation supporting one or more covered clinical indications.

Therapy Overview

Proton beam therapy is a form of external radiation therapy that uses protons or other charged particles, such as helium ions, to target a tissue mass precisely while limiting radiation scatter. Charged-particle therapy may provide clinical benefit in selected cases by improving normal-tissue sparing, permitting dose escalation, or reducing cumulative radiation exposure. Coverage depends on the tumor type, patient age, clinical circumstances, and whether the application is considered investigational.

Policy Definitions

Proton beam therapy

DefinitionA form of external radiation therapy consisting of protons precisely targeted to a specific tissue mass

Also known asCharged-particle radiotherapy

Treatment typeExternal radiation therapy

AYA

MeaningAdolescents and young adults

Age range22 through 39 years

Policy terminologyAYA

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyCharged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Policy CodePolicy 8.01.VT10

Change TypeUpdated indications and criteria

Effective DateFebruary 1, 2026

Last ReviewOct 1, 2025

Next Review DateOctober 1, 2026

Key ActionObtain prior approval and submit the required clinical documentation for listed stereotactic radiosurgery and proton treatment-delivery services.

SourceLink

On This Page

Spine or spinal cord tumor: The patient has a primary spine or spinal cord tumor, or a metastatic tumor to the spine for which conventional treatment could exceed spinal cord tolerance, or the area was previously irradiated

Craniospinal irradiation: The primary or metastatic tumor requires craniospinal irradiation

Pleural mesothelioma: The patient has malignant pleural mesothelioma

Localized unresectable hepatocellular carcinoma: The patient has localized, unresectable hepatocellular carcinoma treated with curative intent, and standard radiation therapy is contraindicated or not technically feasibleLocalized; unresectable; curative intent

Standard radiation therapy must be contraindicated or not technically feasible.

Previously irradiated area: The same or an immediately adjacent area was previously irradiated, and the dose distribution must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue

Comprehensive list of cancer therapies and medications, including chemotherapy and prior radiation to the same or an immediately adjacent area.

Treatment prescription stating treatment goals, dose-volume parameters for the target and nearby critical structures, and pertinent beam-delivery details.

Documentation Required

Support the Charged-Particle Rationale

Documentation must explain why photon-based radiotherapy cannot adequately spare surrounding normal tissue and why charged-particle treatment provides added clinical benefit. Identify the applicable dose-sparing or toxicity rationale for the proposed treatment.

Target near critical structures requiring a steep dose gradient.
Need to reduce dose inhomogeneity and avoid an excessive treatment-volume hotspot.
Photon technique would create a clinically meaningful normal-tissue toxicity risk based on integral dose.
Previously irradiated or immediately adjacent area requiring sculpting to avoid exceeding cumulative normal-tissue tolerance.

Unsupported block type: denial_risk

Denial Risk

When Criteria Are Not Met

Coverage criteria are not met when the proposed treatment falls outside the covered tumor sites, age groups, disease characteristics, or specified anatomic and re-irradiation circumstances. Applications that do not satisfy the policy’s listed indications may be denied.

Adult application is not one of the listed covered indications, including clinically localized prostate cancer or non-small-cell lung cancer at any stage or for recurrence.
Ocular tumor exceeds 24 mm in diameter or 14 mm in height, or has metastasis or extrascleral extension.
Hepatocellular carcinoma is not localized and unresectable, is not treated with curative intent, or standard radiation is not contraindicated or technically infeasible.
Spine or spinal cord tumor does not involve circumstances in which conventional treatment would exceed spinal cord tolerance or the area was previously irradiated.
Proposed treatment does not meet the applicable age, tumor-site, resectability, disease-status, anatomy, genetic-risk, dose-escalation, or re-irradiation criteria.

Unsupported block type: prior_auth

Denial Risk

Audit and Recoupment Risk

Blue Cross Blue Shield of Vermont may audit any provider or facility for compliance with this medical policy. If an audit identifies noncompliance, Blue Cross VT may recoup all non-compliant payments.

Maintain records demonstrating compliance with the policy guidelines.
Non-compliant payments are subject to recoupment.

Investigational application

DefinitionA charged-particle application in an adult over age 21 that is not among the policy's listed medically necessary indications

Age thresholdOver age 21

Coverage statusConsidered investigational